Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6

被引:89
作者
Liu, Shih-Jen
Tsai, Jy-Ping
Shen, Chia-Rui
Sher, Yuh-Pyng
Hsieh, Chia-Ling
Yeh, Yu-Ching
Chou, Ai-Hsiang
Chang, Shu-Rung
Hsiao, Kuang-Nan
Yu, Feng-Wei
Chen, Hsin-Wei
机构
[1] Natl Hlth Res Inst, Vaccine Res & Dev Ctr, Zhunan 350, Taiwan
[2] Chang Gung Univ, Grad Inst Med Biotechnol, Tao Yuan, Taiwan
[3] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan
[4] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan
关键词
IL-17; mixed lymphocyte culture; cytotoxic T lymphocyte;
D O I
10.1189/jlb.0207111
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cross-talk between TGF-beta and IL-6 has been shown to direct the differentiation of CD4(+) cells into special IL-17-secreting cells, which are termed Th17 cells. In this study, we demonstrated that TGF-beta and IL-6 could stimulate CD8(+) cells to differentiate into noncytotoxic, IL-17-producing cells in MLC. These IL-17-producing CD8(+) cells exhibit a unique granzyme B- IFN-gamma-IL-10-phenotype. The mRNA level of Th2/T cytotoxic 2 (Tc2) transcription factors GATA3 and Th1/Tc1 transcription factors T-box expressed in T cell (T-bet) as well as its target H2 center dot O-like homeobox (Hlx) is decreased in CD8(+) cells from TGF-beta and IL-6-treated MLC. In addition, these CD8(+) cells display a marked up-regulation of retinoic acid-related orphan receptor-gamma t, a key IL-17 transcription factor. These results demonstrate that the existence of an IL-17producing CD8(+) subset belongs to neither the Tc1 nor the Tc2 subset and can be categorized as a T noncytotoxic 17 (Tnc17) subset.
引用
收藏
页码:354 / 360
页数:7
相关论文
共 47 条
  • [1] Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism
    Benchetrit, F
    Ciree, A
    Vives, V
    Warnier, G
    Gey, A
    Sautès-Fridman, C
    Fossiez, F
    Haicheur, N
    Fridman, WH
    Tartour, E
    [J]. BLOOD, 2002, 99 (06) : 2114 - 2121
  • [2] Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
    Bettelli, E
    Carrier, YJ
    Gao, WD
    Korn, T
    Strom, TB
    Oukka, M
    Weiner, HL
    Kuchroo, VK
    [J]. NATURE, 2006, 441 (7090) : 235 - 238
  • [3] CARTER LL, 1995, J IMMUNOL, V155, P1028
  • [4] Type 1 and Type 2: A fundamental dichotomy for all T-cell subsets
    Carter, LL
    Dutton, RW
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (03) : 336 - 342
  • [5] Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection
    Cerwenka, A
    Morgan, TM
    Harmsen, AG
    Dutton, RW
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (02) : 423 - 434
  • [6] Cerwenka A, 1998, J IMMUNOL, V161, P97
  • [7] Chabaud M, 1998, J IMMUNOL, V161, P409
  • [8] Liposome encapsulation of fluorescent nanoparticles: Quantum dots and silica nanoparticles
    Chen, Chien-Sheng
    Yao, Jie
    Durst, Richard A.
    [J]. JOURNAL OF NANOPARTICLE RESEARCH, 2006, 8 (06) : 1033 - 1038
  • [9] Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3
    Chen, WJ
    Jin, WW
    Hardegen, N
    Lei, KJ
    Li, L
    Marinos, N
    McGrady, G
    Wahl, SM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) : 1875 - 1886
  • [10] Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses
    Dobrzanski, MJ
    Reome, JB
    Hollenbaugh, JA
    Dutton, RW
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (03) : 1380 - 1390